Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Catalyst Biosciences presents data from MAA-201 study of MarzAA

Feb. 14, 2019

Beijing Sanyou Liheze Biological Technology describes anticoagulant fusion protein

Feb. 12, 2019

uniQure presents updated data from phase IIb study of AMT-061 in hemophilia B

Feb. 11, 2019

FDA approves Cablivi for treatment of aTTP

Feb. 7, 2019

Phase III study of Ultomiris in aHUS meets primary objective of complete TMA response

Jan. 28, 2019

Intrabone gene therapy with autologous HSCs for transfusion-dependent beta-thalassemia: phase I/II

Jan. 28, 2019

Attune Pharmaceuticals presents promising data for ATN-249 in hereditary angioedema

Jan. 25, 2019

Bioverativ begins phase I/II study of BIVV-003 in sickle cell disease

Jan. 14, 2019

Protagonist Therapeutics initiates phase II study of PTG-300 in patients with beta-thalassemia

Jan. 11, 2019

Common mechanism links diverse anemias

Jan. 11, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Viva in vivo! At EHA, in vivo CAR T data continues to impress
BioWorld
Treatment with first-generation CAR T cells regularly sent patients to the intensive care unit. Now, investigators are envisioning a future where CAR T treatment...